Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ProPhase Labs (PRPH) EBITDA (2016 - 2025)

Historic EBITDA for ProPhase Labs (PRPH) over the last 16 years, with Q3 2025 value amounting to -$6.8 million.

  • ProPhase Labs' EBITDA fell 387.18% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.7 million, marking a year-over-year decrease of 5732.39%. This contributed to the annual value of -$53.3 million for FY2024, which is 19857.05% down from last year.
  • ProPhase Labs' EBITDA amounted to -$6.8 million in Q3 2025, which was down 387.18% from -$4.5 million recorded in Q2 2025.
  • In the past 5 years, ProPhase Labs' EBITDA ranged from a high of $12.5 million in Q1 2022 and a low of -$34.4 million during Q4 2024
  • Over the past 5 years, ProPhase Labs' median EBITDA value was -$2.9 million (recorded in 2023), while the average stood at -$2.8 million.
  • In the last 5 years, ProPhase Labs' EBITDA skyrocketed by 116964.47% in 2021 and then plummeted by 520869.57% in 2024.
  • ProPhase Labs' EBITDA (Quarter) stood at $10.5 million in 2021, then plummeted by 113.29% to -$1.4 million in 2022, then plummeted by 443.36% to -$7.6 million in 2023, then plummeted by 351.69% to -$34.4 million in 2024, then skyrocketed by 80.09% to -$6.8 million in 2025.
  • Its EBITDA was -$6.8 million in Q3 2025, compared to -$4.5 million in Q2 2025 and $4.0 million in Q1 2025.